Search - tctmd.com

Displaying 401 - 420 of 4671

Sort: Relevancy | Date

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

News Daily News

Tricuspid TEER Continues to Offer Benefits Through 3 Years: TRILUMINATE

September 12, 2024

More Data Diminish Support for Cath Lab Fasting Rules: SCOFF

News Conference News ESC 2024

More Data Diminish Support for Cath Lab Fasting Rules: SCOFF

September 10, 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

Using Potassium to Prevent AF After CABG? Don’t Do That, TIGHT-K Indicates

News Conference News ESC 2024

Using Potassium to Prevent AF After CABG? Don’t Do That, TIGHT-K Indicates

September 05, 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

News Conference News ESC 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

September 04, 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

September 03, 2024

SHAM-PVI Catheter Ablation Improves Objective Measure of AF Burden

News Conference News ESC 2024

SHAM-PVI: Catheter Ablation Improves Objective Measure of AF Burden

September 02, 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

News Conference News ESC 2024

Asundexian for AF? More Details on the Sinking of OCEANIC-AF

September 02, 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

News Conference News ESC 2024

MitraClip vs Surgery for Severe FMR? MATTERHORN Claims Noninferiority

September 01, 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

News Conference News ESC 2024

Trial Challenges Continuation of Oral Anticoagulants During TAVI

August 31, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presentation ESC 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presenter: Stefano Taddei

August 31, 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

News Conference News ESC 2024

ABYSS: Safety Signal Seen When Beta-blockers Stopped in Post-MI Patients

Michael O'Riordan

August 30, 2024

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

News Daily News

AUGUSTUS Analysis Clarifies Antithrombotic Choice for ACS in AF Patients

Michael O'Riordan

August 26, 2024

Scientific Statement Reviews Current Antithrombotic Options in PAD

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

August 26, 2024

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

News Daily News

Study Supports Cost-effectiveness of Renal Denervation for Hypertension

August 23, 2024

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

News Daily News

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Michael O'Riordan

August 21, 2024

Going Contrast Free in TAVI Is Safe for CKD Patients

News Daily News

Going Contrast Free in TAVI Is Safe for CKD Patients

August 20, 2024

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

News Daily News

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Yael L. Maxwell

August 19, 2024

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

August 19, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.